Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01233505 · ClinicalTrials.gov registry record · Phase 1
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01233505: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01233505 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01233505, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and the best dose of veliparib when given together with capecitabine and oxaliplatin in treating patients with advanced solid tumors. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with capecitabine and oxaliplatin may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG oxaliplatin
- DRUG capecitabine
- OTHER pharmacological study
- DRUG veliparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01233505
The ClinicalTrials.gov registry entry for NCT01233505 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01233505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01233505 about?
NCT01233505 is a clinical study titled "Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors". This phase I trial is studying the side effects and the best dose of veliparib when given together with capecitabine and oxaliplatin in treating patients with advanced solid tumors. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in che...
What is the current status of trial NCT01233505?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-10.
What interventions are being tested in trial NCT01233505?
The interventions under investigation include: laboratory biomarker analysis (OTHER), oxaliplatin (DRUG), capecitabine (DRUG), pharmacological study (OTHER), veliparib (DRUG).
Who is sponsoring clinical trial NCT01233505?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.